NCT03361306 2026-03-06LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple MyelomaWake Forest University Health SciencesPhase 2 Completed15 enrolled 26 charts
NCT06163040 2025-07-31A Study to Evaluate the Safety of EmplicitiĀ® (Elotuzumab) When Treating Patients With Multiple Myeloma in TaiwanBristol-Myers SquibbCompleted7 enrolled